Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial

AIMS/HYPOTHESIS: After coronary artery bypass graft (CABG) surgery in individuals with type 2 diabetes, there remains a considerable residual cardiovascular risk. In the EMPA-REG OUTCOME® trial in participants with type 2 diabetes and established cardiovascular disease, empagliflozin reduced the ris...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Subodh, Mazer, C. David, Fitchett, David, Inzucchi, Silvio E., Pfarr, Egon, George, Jyothis T., Zinman, Bernard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061159/
https://www.ncbi.nlm.nih.gov/pubmed/29777264
http://dx.doi.org/10.1007/s00125-018-4644-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6061159/
https://www.ncbi.nlm.nih.gov/pubmed/29777264
http://dx.doi.org/10.1007/s00125-018-4644-9

Ejemplares similares